Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety, Immunogenicity and Efficacy of a Tetravalent Dengue VLP Vaccine (VLPDEN-02) Against DENV-3 Challenge in Healthy Adults

NCT07831473 is registered in ClinicalTrials.gov with VLP Therapeutics as lead sponsor.

NCT NCT07831473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07831473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety, Immunogenicity and Efficacy of a Tetravalent Dengue VLP Vaccine (VLPDEN-02) Against DENV-3 Challenge in Healthy Adults
Lead sponsor
VLP Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 4, 2027
Completion date
May 15, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

challenge test, dengue, dose escalation and safety, double blind, randomised clinical trial